Bone Biologics Corp

For the period ended Jun 30, 2024. Filed Aug 9, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 9, 2024

BBLG$0.34+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Statements of Cash Flows

Condensed Consolidated Statements of Cash Flows

Six months Ended June 30, 2024 · Six months Ended June 30, 2023
(unaudited) · (unaudited)
Cash flows from operating activities
Net loss		$(1,649,703)		$(5,479,137)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		70,124		61,434
Change in fair value of warrant liability		(48,096)		(707,284)
Changes in operating assets and liabilities:
Advances on research and development contract services		(321,431)		170,205
Prepaid insurance and prepaid expenses		171,229		171,482
Accounts payable and accrued expenses		(51,390)		706,881
Research and development contract liabilities		44,980		93,753
Accrued legal settlement		(414,989)		-
Net cash used in operating activities		(2,199,276)		(4,982,666)
Cash flows from financing activities
Proceeds from sale of common stock in public offering, net of offering costs		1,504,339		4,452,163
Exercise of pre-funded warrants		436		-
Net cash provided by financing activities		1,504,775		4,452,163
Net decrease in cash		(694,501)		(530,503)
Cash, beginning of period		3,026,569		7,538,312
Cash, end of period		$2,332,068		$7,007,809
Supplemental information
Income taxes paid	$	-	$	-
Noncash investing and financing activities
Options issued to settle accrued bonus		$77,400		-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.